National MS Society Invests in Commercial Research by TG Therapeutics for Development of Oral TGR-1202 (umbralisib) to Treat Progressive MS
October 2, 2017
The National MS Society, through Fast Forward, will invest up to $254,452 to enable TG Therapeutics, Inc. to further the laboratory testing of TGR-1202 (umbralisib) as a potential oral treatment option for progressive MS. Renowned MS researcher Dr. Lawrence Steinman, of Stanford University, will lead the research team on this effort.
This investment stemmed from a request for proposals released by Fast Forward for projects focused on testing existing therapies or drug candidates to determine if they protect the nervous system from damage and/or repair damage, especially for the treatment of progressive MS. TGR-1202 is already being tested in people with blood cancers, so it is ready for testing in MS if the lab testing suggests potential benefit.
“We are hopeful that these proof of concept studies will support the rationale for further clinical development of TGR-1202 for progressive forms of MS, for which there are few treatment options,” said Mark Allegretta, PhD, Associate Vice President of Commercial Research at the Society. “This investment exemplifies our effort to identify clinic-ready candidates to expand the pipeline of therapies being tested for use in MS.”
TGR-1202 uses a novel mechanism to inhibit the production of immune B cells, which are known to be involved in MS disease activity. Another B-cell therapy, Ocrevus™ (ocrelizumab - Genentech, a member of the Roche Group), was recently approved for both primary progressive and relapsing MS.
Read more about Fast Forward
Read more about research in progressive MS
Ocrevus is a Trademark of Genentech, a member of the Roche Group